Nektar Therapeutics (NKTR) Assets Average (2011 - 2026)

Nektar Therapeutics' Assets Average history runs 16 years deep, the most recent figure standing at $521.8 million for Q1 2026.

• In Q1 2026, Assets Average rose 86.34% year-over-year to $521.8 million; the TTM figure through Mar 2026 stood at $521.8 million (up 86.34% YoY), while the FY2025 annual figure was $292.1 million, down 16.76% from the prior year.
• Assets Average for Q1 2026 stood at $521.8 million, up from $290.9 million in the prior quarter.
• The five-year high for Assets Average was $1.1 billion in Q1 2022, with the low at $231.9 million in Q2 2025.
• The 5-year median for Assets Average is $420.1 million (2023), against an average of $506.5 million.
• The sharpest annual moves came in 2023 and 2026: Assets Average sank 44.01% in 2023, then surged 86.34% in 2026.
• Nektar Therapeutics' Assets Average stood at $745.8 million in 2022, then slumped by 43.67% to $420.1 million in 2023, then declined by 27.19% to $305.9 million in 2024, then slipped by 4.91% to $290.9 million in 2025, then soared by 79.4% to $521.8 million in 2026.
• Business Quant data shows NKTR's Assets Average at $521.8 million in Q1 2026, $290.9 million in Q4 2025, and $254.4 million in Q3 2025.